<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the protease inhibitors </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEFLOQUINE" rxcui="6694">
<ATC code="P01BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
<ATC code="J04AM02" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
